Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders

SANTA FE, N.M., Sept. 17, 2025 /PRNewswire/ -- Frame Bio, a biotechnology company developing therapeutics for structural diseases and disorders, announced today an exclusive licensing agreement with Mercury Bio, a drug delivery company leveraging its novel extracellular vesicle (EV) drug...